Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Election of Directors
Director Nominees |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||||||
FOR |
WITHHELD |
FOR |
WITHHELD |
|||||
|
4,616,653 |
|
148,815 |
|
|
|
|
|
|
4,378,536 |
|
386,932 |
|
|
|
|
|
|
4,363,268 |
|
402,200 |
|
|
|
|
|
|
4,375,612 |
|
389,856 |
|
|
|
|
|
|
4,692,345 |
|
73,123 |
|
|
|
|
|
|
4,705,132 |
|
60,336 |
|
|
|
|
Appointment of External Auditors
Outcome |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||||||
FOR |
WITHHELD |
FOR |
WITHHELD |
|||||
|
5,442,357 |
15,130 |
|
|
Approval of the Continuation of Crescita’s Shareholder Rights Plan
Outcome |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||||||
FOR |
AGAINST |
FOR |
AGAINST |
|||||
Shareholder Rights Plan approved |
4,648,487 |
116,981 |
|
|
About
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For further details, visit www.crescitatherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512006074/en/
Investor Relations
Email: lkisa@crescitatx.com
Source:
Source: